{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Episodic+Migraine+Headache",
    "query": {
      "condition": "Episodic Migraine Headache"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 82,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Episodic+Migraine+Headache&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-07-23T04:11:58.665Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02025556",
      "title": "A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Episodic Migraine Headache"
      ],
      "interventions": [
        {
          "name": "LBR-101 High Dose",
          "type": "DRUG"
        },
        {
          "name": "LBR-101 Low Dose",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Teva Branded Pharmaceutical Products R&D, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 297,
      "start_date": "2014-01-31",
      "completion_date": "2015-03-31",
      "has_results": true,
      "last_update_posted_date": "2022-01-24",
      "last_synced_at": "2026-07-23T04:11:58.665Z",
      "location_count": 63,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 56 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Anaheim",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02025556"
    },
    {
      "nct_id": "NCT06323928",
      "title": "A Dose-finding Trial With Lu-AG09222 in Adults With Migraine Who Have Not Been Helped by Prior Preventive Treatments",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "Lu AG09222",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "H. Lundbeck A/S",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 874,
      "start_date": "2024-04-01",
      "completion_date": "2026-03-16",
      "has_results": false,
      "last_update_posted_date": "2026-06-12",
      "last_synced_at": "2026-07-23T04:11:58.665Z",
      "location_count": 28,
      "location_summary": "Hoover, Alabama • Carlsbad, California • Fullerton, California + 24 more",
      "locations": [
        {
          "city": "Hoover",
          "state": "Alabama"
        },
        {
          "city": "Carlsbad",
          "state": "California"
        },
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Los Alamitos",
          "state": "California"
        },
        {
          "city": "Sherman Oaks",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06323928"
    },
    {
      "nct_id": "NCT01257893",
      "title": "Aspirin Resistance in Women With Migraine",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Episodic Migraine",
        "Chronic Migraine"
      ],
      "interventions": [
        {
          "name": "Aspirin (acetylsalicylic acid)",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Swedish Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 50 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2010-11",
      "completion_date": "2012-08",
      "has_results": false,
      "last_update_posted_date": "2013-05-31",
      "last_synced_at": "2026-07-23T04:11:58.665Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01257893"
    },
    {
      "nct_id": "NCT03716505",
      "title": "Non-invasive Vagus Nerve Stimulation for the Prevention of Migraines",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Migraine Disorders"
      ],
      "interventions": [
        {
          "name": "gammaCore Sapphire active",
          "type": "DEVICE"
        },
        {
          "name": "gammaCore Sapphire Sham",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "DEVICE"
      ],
      "sponsor": "ElectroCore INC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 231,
      "start_date": "2018-11-02",
      "completion_date": "2020-09-09",
      "has_results": false,
      "last_update_posted_date": "2020-09-11",
      "last_synced_at": "2026-07-23T04:11:58.665Z",
      "location_count": 30,
      "location_summary": "Scottsdale, Arizona • Carlsbad, California • Palo Alto, California + 27 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Carlsbad",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03716505"
    },
    {
      "nct_id": "NCT04252742",
      "title": "Erenumab - Comprehensive Assessment of Efficacy in (High-Frequency) Episodic Migraine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "Erenumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 512,
      "start_date": "2020-09-15",
      "completion_date": "2023-10-26",
      "has_results": true,
      "last_update_posted_date": "2026-03-31",
      "last_synced_at": "2026-07-23T04:11:58.665Z",
      "location_count": 31,
      "location_summary": "Long Beach, California • Los Angeles, California • Basalt, Colorado + 28 more",
      "locations": [
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Basalt",
          "state": "Colorado"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Englewood",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04252742"
    },
    {
      "nct_id": "NCT05127486",
      "title": "A Study of Galcanezumab (LY2951742) in Adult Participants With Episodic Migraine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Migraine",
        "Episodic Migraine"
      ],
      "interventions": [
        {
          "name": "Galcanezumab",
          "type": "DRUG"
        },
        {
          "name": "Rimegepant",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 580,
      "start_date": "2021-12-06",
      "completion_date": "2023-05-23",
      "has_results": true,
      "last_update_posted_date": "2024-06-28",
      "last_synced_at": "2026-07-23T04:11:58.665Z",
      "location_count": 77,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Tempe, Arizona + 71 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Banning",
          "state": "California"
        },
        {
          "city": "Chula Vista",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05127486"
    },
    {
      "nct_id": "NCT05734625",
      "title": "Efficacy of Nerve Blocks for Episodic Migraine",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Episodic Migraine"
      ],
      "interventions": [
        {
          "name": "Bupivacaine HCl 0.5% Injectable Solution",
          "type": "DRUG"
        },
        {
          "name": "Methylprednisolone 40 MG Injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 60,
      "start_date": "2023-07-10",
      "completion_date": "2027-07",
      "has_results": false,
      "last_update_posted_date": "2026-06-16",
      "last_synced_at": "2026-07-23T04:11:58.665Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05734625"
    },
    {
      "nct_id": "NCT01230411",
      "title": "Pilot Study to Collect and Evaluate Data on the Use of IV* Ibuprofen in the Treatment of an Acute Migraine Attack",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Episodic Migraine"
      ],
      "interventions": [
        {
          "name": "saline placebo",
          "type": "OTHER"
        },
        {
          "name": "Ibuprofen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "OTHER",
        "DRUG"
      ],
      "sponsor": "Thomas Jefferson University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 44,
      "start_date": "2011-06",
      "completion_date": "2017-07",
      "has_results": true,
      "last_update_posted_date": "2022-09-06",
      "last_synced_at": "2026-07-23T04:11:58.665Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01230411"
    },
    {
      "nct_id": "NCT02163993",
      "title": "A Study of Galcanezumab (LY2951742) in Participants With Migraine Headache",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Migraine Headache"
      ],
      "interventions": [
        {
          "name": "Galcanezumab",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 414,
      "start_date": "2014-07-07",
      "completion_date": "2018-02-12",
      "has_results": true,
      "last_update_posted_date": "2018-11-23",
      "last_synced_at": "2026-07-23T04:11:58.665Z",
      "location_count": 40,
      "location_summary": "Gilbert, Arizona • Phoenix, Arizona • Encino, California + 34 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Encino",
          "state": "California"
        },
        {
          "city": "Long Beach",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02163993"
    },
    {
      "nct_id": "NCT05217927",
      "title": "Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Migraine"
      ],
      "interventions": [
        {
          "name": "Rimegepant 75mg daily dosing",
          "type": "DRUG"
        },
        {
          "name": "Rimegepant 75mg every other day dosing",
          "type": "DRUG"
        },
        {
          "name": "Placebo comparator dosing",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1415,
      "start_date": "2022-03-04",
      "completion_date": "2024-12-11",
      "has_results": true,
      "last_update_posted_date": "2025-12-16",
      "last_synced_at": "2026-07-23T04:11:58.665Z",
      "location_count": 30,
      "location_summary": "Tempe, Arizona • Colton, California • Los Angeles, California + 27 more",
      "locations": [
        {
          "city": "Tempe",
          "state": "Arizona"
        },
        {
          "city": "Colton",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Sherman Oaks",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05217927"
    }
  ]
}